RxDoctor Payments Data

Quynh Vo

Adult Health · Phoenix, AZNPI 1538161203

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.2% of the total across 425 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 45 manufacturers, the largest accounting for just 12.4% — the pattern of someone who eats at a lot of different presentations. Among adult health clinicians in AZ with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$7,757in general payments, 2019–2025

Across 425 payments — averaging $18.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$962
  • Amgen$901
  • Merck$656
  • AstraZeneca$468
  • Johnson & Johnson$429
  • Abbott$422
  • plus $4K from 39 others

What the payments were for

  • Food & beverage$7,69699%
  • Education$601%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,757 in reported general payments places this provider in the 90th percentile of 314 adult health providers in Arizona.

See all adult health providers in Arizona

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban216$265,393
EntrestoSacubitril/Valsartan120$179,297
Repatha SureclickEvolocumab108$129,668
FarxigaDapagliflozin Propanediol54$74,780
JardianceEmpagliflozin58$73,157
VascepaIcosapent Ethyl70$58,964
XareltoRivaroxaban37$46,445
OzempicSemaglutide21$28,294
Ezetimibe721$22,658
LivaloPitavastatin Calcium26$15,658
Praluent PenAlirocumab12$14,989
NexlizetBempedoic Acid/Ezetimibe11$13,061
EdarbyclorAzilsartan Med/Chlorthalidone21$12,307
Icosapent Ethyl17$8,356
Rosuvastatin Calcium528$7,769

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$146$265,393216 claims
NovartisEntresto$962$179,297120 claims
AstraZenecaFarxiga$468$74,78054 claims
Boehringer IngelheimJardiance$222$73,15758 claims
Johnson & JohnsonXarelto$429$46,44537 claims
Novo NordiskOzempic$328$28,29421 claims
Kowa Pharmaceuticals America, Inc.Livalo$389$15,65826 claims
Esperion Therapeutics, Inc.Nexlizet$102$13,06111 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 314 adult health providers in Arizona.

Other adult health in Phoenix

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →